U.S. FDA Move “Beyond Our Borders” Begins With China
This article was originally published in PharmAsia News
Executive Summary
Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.
You may also be interested in...
U.S. FDA, PDA Kick Off First Conference On Quality Systems For China’s Manufacturers, Suppliers
SHANGHAI - The U.S. FDA, the Parenteral Drug Association and the respective local Chinese FDA jointly held the first education seminar on quality systems in Shanghai and Beijing in late April
U.S. FDA, PDA Kick Off First Conference On Quality Systems For China’s Manufacturers, Suppliers
SHANGHAI - The U.S. FDA, the Parenteral Drug Association and the respective local Chinese FDA jointly held the first education seminar on quality systems in Shanghai and Beijing in late April
U.S. FDA Triples Estimate On Deaths Following Allergic Reaction To Blood Thinner Heparin
BEIJING - U.S. FDA last week issued a sharply higher estimate on the number of deaths that have occurred in patients who suffered allergic reactions to the blood thinner heparin